NYSE$DDD

3D Systems Corp. · Q2 2023 earnings

Q2 2023 earnings · · Investor relations

Briefing

3D Systems reported a decrease in revenue due to lower sales in the dental orthodontics market, while also seeing growth in non-dental markets and investing in regenerative medicine.

3D Systems reported a decrease in revenue for Q2 2023, primarily due to lower sales in the dental orthodontics market. However, the company saw growth in non-dental markets and continued to invest in regenerative medicine. They are adjusting their full-year 2023 revenue expectation to $525 million to $545 million and anticipate positive adjusted EBITDA in Q4 2023.

  • Revenue decreased by 8.5% to $128.194 million compared to the same period last year, with a decrease of 8.7% on a constant currency basis.
  • The decline in revenue primarily reflects lower sales to certain dental orthodontic market customers due to macroeconomic factors.
  • Healthcare Solutions revenue decreased by 15.2% to $60.874 million compared to the same period last year, while Industrial Solutions revenue decreased by 1.4% to $67.320 million.
  • The company is adjusting its full-year 2023 revenue expectation to $525 million to $545 million and expects positive adjusted EBITDA in Q4 2023.

Headline financials

Total Revenue

$128M

Previous: $140M-8.5%
EPS (adj)

-$0.07

Previous: -$0.07+0.0%
Capital Expenditures

-$13.5M

Previous: -$10.4M-30.7%
Free Cash Flow

-$42.4M

Previous: -$43.3M+2.0%
Net Income

-$28.9M

Previous: -$33M+12.3%
Operating Income

-$31.7M

Previous: -$32M+1.0%
Gross Profit

$50M

Previous: $53.1M-5.9%
Cash & Equivalents

$490M

Previous: $299M+64.1%
Total Assets

$1.43B

Previous: $1.48B-3.4%
Stock-Based Comp

$7.99M

Previous: $7.4M+7.9%

Revenue & EPS history

3D Systems · Revenue · Quarterly

$128M

Q2 2023-8.5%vs Q2 2022
Beat estimate in 4 of 14 quarters(29%)
ActualEstimate

Revenue by segment

3D Systems · $128M total across 2 segments · Q2 2023

  • Industrial Solutions
    $67.3M
  • Healthcare Solutions
    $60.9M

Forward guidance

3D Systems is revising its full-year 2023 revenue expectation to $525 million to $545 million, and would now expect positive adjusted EBITDA in Q4’23. This includes the full year investment of roughly $10 million in our regenerative medicine business.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q2 2023

Historical avgQ2 2023

-2.5%

Avg return

Earnings day

-3.7%

Avg return

5 days after

-0.9%

Avg return

30 days after

38%

25 / 65 earnings

Positive

+34.5%

Q2 2018

Best reaction

-27.8%

Q1 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+1.2%+21.9%+16.6%
Q4 2025-1.9%+23.5%-2.0%
Q3 2025-0.8%-13.4%-17.6%
Q1 2025-27.8%-32.5%-31.8%
Q4 2024-21.0%-23.9%-28.7%
Q3 2024-14.0%-13.4%+1.2%
Q2 2024-7.0%-17.0%+25.7%
Q1 2024+0.0%+1.5%+1.2%
Q4 2023-22.2%-18.2%-14.1%
Q3 2023-1.9%-0.7%+40.3%
Q2 2023-12.0%-11.3%-34.8%
Q1 2023-9.4%-10.1%+8.8%
Q4 2022+10.2%+12.9%+1.0%
Q3 2022+4.6%+28.3%+21.8%
Q2 2022-10.7%-1.7%-24.0%
Q1 2022-7.9%-6.0%-0.5%
Q4 2021-1.0%-16.2%-2.2%
Q3 2021-10.3%-20.7%-27.2%
Q2 2021+24.5%+9.0%+12.3%
Q1 2021+25.1%+16.2%+55.4%
Q4 2020-13.0%-36.2%-30.3%
Q3 2020+5.6%+23.7%+77.0%
Q2 2020-8.3%-9.4%-20.9%
Q1 2020-10.4%-11.2%-2.6%
Q4 2019-8.1%-10.1%-30.0%
Q3 2019+8.3%+11.1%-3.1%
Q2 2019-14.3%-13.6%-8.9%
Q1 2019-22.2%-21.2%-23.3%
Q4 2018-14.7%-18.0%-24.4%
Q3 2018-22.7%-17.3%-20.2%
Q2 2018+34.5%+48.9%+39.9%
Q1 2018-10.5%-3.4%+19.7%
Q4 2017+7.0%+0.3%-0.7%
Q3 2017-20.1%-23.9%-25.3%
Q2 2017-21.6%-24.1%-24.8%
Q1 2017-1.5%+16.4%+26.6%
Q4 2016-10.9%-14.2%-12.5%
Q3 2016-4.7%+3.7%+3.6%
Q2 2016+17.1%+26.1%+22.5%
Q1 2016-9.3%
Q4 2015+9.4%
Q3 2015+0.1%
Q2 2015+14.7%
Q1 2015-8.6%
Q4 2014+1.5%
Q3 2014+0.4%
Q2 2014-14.5%
Q1 2014-3.9%
Q4 2013+0.3%
Q3 2013+6.9%
Q2 2013-6.5%
Q1 2013+5.3%
Q4 2012-7.5%
Q3 2012+18.8%
Q2 2012+9.6%
Q1 2011+3.6%
Q1 2012+3.6%
Q4 2009+15.4%
Q4 2011+15.4%
Q1 2010+15.4%
Q3 2011-16.3%
Q3 2010-16.3%
Q2 2011-2.7%
Q2 2010-2.7%
Q4 2010-2.7%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro